ALTSTATION.IO

Boston Scientific Corporation (BSX) Stock Analysis

By Nova Skye | AltStation.io | Updated September 19, 2026

Price

$47.80

Change

+1.81%

Market Cap

$69.27B

Avg Volume

19.8M

Company Overview

Boston Scientific Corporation is a Marlborough, Massachusetts-based medical device manufacturer operating in the healthcare sector since its incorporation in 1979. The company designs, builds, and sells specialized interventional hardware directly to hospitals, outpatient clinics, and surgical specialists worldwide. Its business is split across two core operating segments: MedSurg and Cardiovascular. The product lineup spans critical therapeutic areas, from single-use SpyGlass scopes and urological lasers to WATCHMAN FLX cardiac implants and spinal cord stimulator systems.

Boston Scientific holds a dominant market position across several high-barrier interventional categories rather than functioning as a broad generalist. Its competitive edge relies on proprietary clinical hardware like left atrial appendage closure implants and single-use duodenoscopes that solve hospital infection risks. The primary threat to its business comes from rival medical device giants competing directly for cath-lab shelf space and procedure volume. Maintaining leadership requires heavy capital deployment into clinical trials and strict patent defense across every product line.

Operationally, the company is compounding its footprint by driving adoption in less-invasive cardiac therapies, peripheral vascular treatments, and neuromodulation for chronic pain. Its two-segment portfolio provides strong structural balance, pairing high-volume consumables like stents and catheters with high-value implantable defibrillators and deep brain stimulation hardware. Rather than pivoting away from its core, Boston Scientific is doubling down on specialized devices that shorten procedure times and reduce hospital stays. BSX stands as a focused medical device powerhouse with entrenched global distribution and no unnecessary conglomerate baggage.

Key Financials

Market Cap

$69.27B

Revenue

$21.00B

EBITDA

$5.71B

Gross Margin

69.2%

Profit Margin

17.5%

Revenue Growth

7.5%

Total Cash

$539.00M

Total Debt

$12.62B

Free Cash Flow

$2.45B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

19.35

Forward P/E

13.92

Beta

0.57

52-Week High

$109.50

52-Week Low

$42.20

EPS

$2.47

50-Day Avg

$46.89

200-Day Avg

$66.76

Price/Book

2.77

Technical Analysis

BSX trades at $47.80, just 8% of the way from its $42.20 52-week low to its $109.50 high. The stock is 56.35% below that high but remains 13.27% above the low. Price sits 3.46% below the 20-day moving average of $49.51, confirming weak short-term positioning. Five-day momentum is positive at 2.05%, while 20-day momentum remains negative at 3.06%. Near-term support is $45.51, and resistance is $52.01.

Recent News and Developments

Boston Scientific restores most shipping after cyberattack

Boston Scientific said September 3 that unauthorized access was limited to select internal-facing IT infrastructure. The company began restoring shipping for most products at major global distribution centers, but warned that clearing the order backlog would take time. Source: Boston Scientific

FDA flags serious Infinion CX lead recall

The FDA said Boston Scientific is removing unused Infinion CX spinal cord stimulator leads because mechanical stress can cause high impedance or lead fractures. Boston Scientific reported 1,081 serious injuries and no deaths as of May 27, 2026; already implanted devices are not included in the removal. Source: U.S. Food and Drug Administration

Zacks keeps BSX at Strong Sell despite cardiology growth

Zacks reported September 4 that Boston Scientific’s Interventional Cardiology and Vascular Therapies sales increased 15% year over year during the second quarter of 2026. The research firm assigned BSX its Rank #5 Strong Sell rating while noting that the SEISMIQ 4CE catheter is planned for launch in the first half of 2027. Source: Zacks

Market Sentiment and Analyst Recommendations

Bull Case

Boston Scientific generated $21.00 billion in revenue with 7.5% revenue growth. Its Interventional Cardiology and Vascular Therapies sales increased 15% year over year during the second quarter of 2026, showing strength in a major business segment. The stock trades at $47.80 versus an analyst target of $62.69. The analyst target range reaches as high as $94.00, and the consensus recommendation is buy across 29 analysts. BSX also rebounded 1.81% on September 4 after falling 2.94% on September 3. The bull case is straightforward: revenue is growing, cardiology sales are expanding faster than companywide revenue, and the consensus target sits well above the current price.

Bear Case

BSX carries $12.62 billion in total debt against only $539.00 million in cash. That balance-sheet gap leaves less room for operational setbacks. The FDA recall involving unused Infinion CX leads is serious: Boston Scientific reported 1,081 serious injuries and no deaths as of May 27, 2026. The cyberattack also disrupted shipping, and the company warned that clearing the order backlog would take time. Technically, the stock is 56.35% below its 52-week high and 3.46% below its 20-day moving average. Zacks assigned BSX a Rank #5 Strong Sell despite the 15% second-quarter growth in Interventional Cardiology and Vascular Therapies, so the bullish analyst consensus is not universal.

What to Watch

Watch whether BSX holds the $45.51 near-term support level; a break would put the $42.20 52-week low back into focus. On the upside, $49.51 is the first technical hurdle because it is the 20-day moving average. The next test is the $52.01 near-term resistance level. Investors should track how quickly Boston Scientific clears the shipping backlog after restoring most product shipments at major global distribution centers. The Infinion CX recall also needs close attention, particularly any change from the reported 1,081 serious injuries and no deaths as of May 27, 2026. Beyond the next quarter, the planned first-half 2027 launch of the SEISMIQ 4CE catheter is a defined product catalyst.

Analyst Consensus

BUY

Based on 29 analyst opinions

Low Target

$44.00

Mean Target

$62.69

High Target

$94.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Devices

Employees

59,000

Earnings & Dividends

Next Earnings

Oct 28, 2026

EPS (Trailing)

$2.47

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is BSX a good stock to buy?

The consensus recommendation is buy based on 29 analysts, while the stock trades at $47.80. The takeaway is that analysts are bullish, but the price remains below its $49.51 20-day moving average.

What is BSX’s analyst price target?

The analyst target is $62.69, with estimates ranging from $44.00 to $94.00. The takeaway is that the consensus target is above the current $47.80 price.

Is BSX undervalued?

BSX trades at a P/E ratio of 19.35 and has a market capitalization of $69.27 billion. The takeaway is that the provided data does not establish whether that valuation is cheap relative to peers.

What are BSX’s support and resistance levels?

Near-term support is $45.51, while near-term resistance is $52.01. The takeaway is that these are the main 30-day levels to watch around the current $47.80 price.

How far is BSX from its 52-week high?

BSX is 56.35% below its $109.50 52-week high and 13.27% above its $42.20 low. The takeaway is that the stock remains near the bottom of its 52-week range.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated September 19, 2026.